Japan Medical Dynamic Marketing, Inc. · TSE:7600

Japan Medical Dynamic Marketing — FY2023 Earnings Presentation

31 slides from Japan Medical Dynamic Marketing's earnings presentation, May 12, 2023

  1. Slide 1: Financial Results Briefing for the Fiscal Year Ending March 2023

    JMDM Securities code：7600 Financial Results Briefing for the Fiscal Year Ending March 2023 May 12, 2023 Japan Medical Dynamic Marketing,INC. JMDM Representative Director and President Toshiyuki Hironaka Copyright © Japan Medical Dynamic Marketing, INC. All Rights Reserved.

  2. Slide 2: Notes

    Notes The forward-looking statements in this document are based on information currently available to us and certain assumptions that we consider reasonable, and are not intended as a promise by us that they will be realized. Actual results may differ materially due to various factors. Our products

  3. Slide 3: Contents

    -目次- Results for the fiscal year ended March Forecast for the Fiscal Year Ending March 1 ． 31, 2023 P. 4 ２ ． 31, 2024 P.18 - Consolidated net sales P. 5 Strategy for the fiscal year ending March 31, - 2024 (52nd period) P.19 - Consolidated Statements of Income P. 6 - Consolidated Statements of Incom

  4. Slide 4: Results for the fiscal year ended March 31, 2023

    Results for the fiscal year １． ended March 31, 2023 4

  5. Slide 5: Consolidated net sales

    Consolidated net sales 21.3 （Millions of yen） 25,000 Billion vｓ 22/3 +11.0% 20,000 Two 15,000 consecutive Years with 10,000 Record Sales 5,000 0 14/3 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 5

  6. Slide 6: Consolidated Statement of Income

    Consolidated Statement of Income FYE Mar 2023 YoY change 'FYE Mar 2022 Ratio to Amount of Ratio of Ratio to Results Results （Millions of yen , ％） sales change change sales Net sales 21,307 100.0 +2,114 +11.0 19,193 100.0 Cost of Sales 7,315 34.3 +1,111 +17.9 6,204 32.3 SG&A 11,967 56.2 +1,640 +15.9

  7. Slide 7: Prior Year Operating Income Comparison Analysis

    Prior Year Operating Income Comparison Analysis Factors contributing to a ¥630 million decrease in profit for the fiscal year ending March 31, 2023： Impact of yen depreciation on ODEV product purchases and ODEV SG&A expenses (-0.51 bn yen) The increase in SG&A expenses (-570 million yen) due to incr

  8. Slide 8: Consolidated Sales by Major Products

    Consolidated Sales by Major Products FYE Mar 2023 YoY change FYE Mar 2022 Ratio to Amount of Ratio of Ratio to Results Results （Millions of yen , ％） sales change change sales Japan 12,601 59.1 +192 +1.6 12,409 64.7 Joint 4,738 22.2 +18 +0.4 4,719 24.6 Trauma 4,322 20.3 +206 +5.0 4,115 21.4 Spine 3,1

  9. Slide 9: Japanese market

    Japanese martket 9

  10. Slide 10: Sales in Japan [YoY Comparison]

    Sales in Japan 【YoY Comparison】 Full- accounting period 1Q 2Q 3Q 4Q year （Millions of yen） Ratio of increase/decrease from the previous period（%） ＋7.8 ＋3.8 ▲3.4 ▲0.5 ＋1.6 4,000 20.0% 【First Half】 2022 2023 YoY  Increase in the number of cases acquired due to focus on treatment of femoral neck trans

  11. Slide 11: Sales in Japan [Joints]

    Sales in Japan 【Joints】 （Millions of yen） vs 22/3 ＋0.4% Flat growth 5,000 ODEV Products Other products BHA ※1 Steady growth 4,000 THA ※2 Steady growth Entrada Growth 3,000 Intellijoint HIP® navigation system Effects of introduction 2,000 ※1 Bipolar Hip Arthroplasty ※2 Total Hip Arthroplasty 1,000 Ma

  12. Slide 12: Sales in Japan [Trauma]

    Sales in Japan 【Trauma】 （Millions 5,000 of yen） vs 22/3 ＋5.0% Steady growth ODEV products Other products 4,000 Femoral Neck Dislocation Fracture Treatment Products 3,000 PHS (ODEV Products) 2,000 ASULOCK (other Products) 1,000 Double-digit Growth 0 14/3 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 1

  13. Slide 13: Sales in Japan [Spine]

    Sales in Japan 【Spine】 4,000 of yen） （Millions vs 22/3 ＋1.9% ODEV products Other products Steady growth 3,000 Pisces (New ODEV products) Lynx Plate 2,000 (Other product) 1,000 KMC BKP Growth Slowdown 0 14/3 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 13

  14. Slide 14: U.S. markets

    U.S. markets 14

  15. Slide 15: U.S. Sales

    U.S. Sales $66.3M （Thousands of dollars） $65.6M 70,000 60,000 50,000 vs 22/3 ＋5.9% 40,000 30,000 Past Updates on the Highest 20,000 Level 10,000 0 14/3 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 15

  16. Slide 16: U.S. Sales [Comparison with the same period of the previous year]

    U.S. Sales 【Comparison with the same period of the previous year】 accounting period 1Q 2Q 3Q 4Q 通期 （Thousands of dollars） YoY change（%） ▲1.6 ＋5.9 ＋9.0 ＋10.6 +5.9 20,000 20.0% 4Q Double-digit 2022 2023 YoY Growth 10.0% Recovery Supply chain problems (industry-wide) in the first half of the year are i

  17. Slide 17: U.S. Sales [Joint]

    U.S. Sales 【Joint】 （Thousands of dollars） 【Hip】 【Knee】 $42.8M Knee Joint $23.1M 50,000 BKS Revision Knee vs 22/3 ＋0.3% vs 22/3 ＋9.0% maintaining 40,000 above market 30,000 growth 20,000 Hip Joint Impact of new product 10,000 launches by other competitors 0 19/3 20/3 21/3 22/3 23/3 19/3 20/3 21/3 22/

  18. Slide 18: Forecast for the Fiscal Year Ending March 31, 2024

    Forecast for the Fiscal Year ２． Ending March 31, 2024 18

  19. Slide 19: Strategy for the fiscal year ending March 31, 2024

    Strategy for the fiscal year ending March 31, 2024 (52nd period) Aim to increase operating profit based on sales growth Japanese market U.S. market  Nationwide sales of new products for  Strengthening the customer base through artificial joints and Spinal Fixation Devices UHKAS (sponsored by ODEV)

  20. Slide 20: Forecasts: Consolidated Statements of Income

    【Forecasts】 Consolidated Statements of Income FYE Mar 2024 YoY change FYE Mar 2023 Ratio to Amount of Ratio of Ratio to Forecast Results （Millions of yen , ％） sales change change sales Net sales 23,300 100.0 +1,992 +9.3 21,307 100.0 Cost of sales 7,800 33.5 +485 +6.6 7,315 34.3 SG & A 13,000 55.8 +1

  21. Slide 21: Forecasts: Consolidated Sales by Major Products

    【Forecasts】 Consolidated Sales by Major Products FYE Mar 2024 YoY change FYE Mar 2023 Ratio to Amount of Ratio of Ratio to Forecast Results （Millions of yen , ％） sales change change sales Japan 13,580 58.2 +978 +7.8 12,601 59.1 joint 5,260 22.6 +521 +11.0 4,738 22.2 Trauma 4,500 19.3 +177 +4.1 4,322

  22. Slide 22: Forecasts: Changes in Capital Expenditures, etc.

    【Forecasts] Changes in Capital Expenditures, etc. FYE Mar FYE Mar FYE Mar FYE Mar FYE Mar FYE Mar 2019 2020 2021 2022 2023 2024 Results Results Results Results Results （Millions of yen） Forecast Investment in plant 2,075 1,812 1,586 1,665 1,317 2,160 and equipment Depreciation and 1,159 1,385 1,386

  23. Slide 23: Sustainability

    p > D> 2 3. Sustainability » > YD f

  24. Slide 24: Sustainability Initiatives (FYE Mar 2023)

    Sustainability Initiatives (FYE Mar 2023) Category Action Sustainability  Identification of materiality issues  Participation in TCFD Consortium  Formulation of Environmental Policy Environment  TCFD (Consolidated) Disclosure of GHG emission reduction targets  CDP Score Level "B-" Rating  Huma

  25. Slide 25: Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices

    Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices. Japan Medical Dynamic Marketing,INC. E-MAIL WEB SITE Investor Relations Office ir@jmdm.co.jp https://www.jmdm.co.jp/en/

  26. Slide 26: Appendix

    p > D> 2 Appendix » > D> F

  27. Slide 27: Identification of materiality (Key issues)

    ① Identification of materiality (Key issues) Based on our management philosophy of “contributing to healthcare through the development and sale of leading-edge, superior medical devices,” we have identified six materialities, classified into “materiality in business activities” and “materiality in b

  28. Slide 28: Environmental Policy Development and Disclosure

    ② Environmental Policy Development and Disclosure Environment JMDM Group positions environmental initiatives as an important management issue and, as a responsible member of society, aims to be a company that is trusted by society through contributing to the preservation of the global environment an

  29. Slide 29: Disclosure based on TCFD (GHG emissions reduction)

    ③ Disclosure based on TCFD (GHG emissions reduction) Environment We have disclosed our consolidated GHG emissions Scope 1, 2, and 3 for the fiscal years ending March 31, 2020 through March 31, 2022. 【Indicators and Targets】 【Consolidated GHG emissions Scope 1, 2, 3 ：t-CO₂】 （t-CO₂） Scope1 Scope2 Scop

  30. Slide 30: Human Rights Policy Development and Disclosure

    ④ Human Rights Policy Development and Disclosure Social We have formulated and disclosed the "Japan MDM Group Human Rights Policy" in order to promote group-wide efforts to respect human rights and endeavor to fulfill its responsibilities. Human Rights Policy of JMDM Group（Summary） Based on its mana

  31. Slide 31: Promotion of diverse human resources (Career Management System)

    ⑤ Promotion of diverse human resources Social （Career Management System） We have introduced CMS (Career Management System) that allows each employee to consider his or her own career and to develop his or her career through interaction with the company and superiors. In addition, we are promoting th

Japan Medical Dynamic Marketing — FY2023 Earnings Presentation on 6ix